Arent Fox Expands Patent and Life Sciences Teams on Both Coasts
“Daniel and Larry bring more than five decades of combined experience to Arent Fox, and we couldn’t be more excited to welcome them to the firm,” said Richard LaCava, Patent Practice Leader. “Between Daniel’s in-house experience and Larry’s scientific background, they’ll complement our existing IP and Life Sciences teams, providing tailored, strategic, and business-oriented legal advice to our clients.”
Mr. Stelter joins Arent Fox following a 13-year tenure at Cardinal Health, Inc., where he served as the Vice President and Chief Counsel of Intellectual Property. In that capacity, Mr. Stelter was the principal IP counsel leading the IP strategy for a Fortune 20 global health care company with diverse businesses operating in competitive fields such as medical device manufacturing, nuclear imaging manufacturing, pharmaceutical distribution, and healthcare technologies. Earlier in his career, Mr. Stelter was in-house counsel for a global paper and packaging company, as well as for an industrial technologies company that provided multi-million dollar capital equipment to major aerospace and automotive companies.
At Arent Fox, Mr. Stelter brings in-house experience to clients seeking counsel on managing diverse intellectual property portfolios, including patent assets, unpatented inventions, trade secrets, trademark assets, copyrights, design rights, and internet/software rights. He routinely counsels product development and marketing teams as it relates to navigating complex IP landscapes and competitive pressures.
Mr. Stelter also possesses extensive hands-on experience with complex transactions involving intellectual property rights, including technology licensing and complex business mergers, acquisitions, and divestitures. In particular, Mr. Stelter leverages his transactional experience to provide counsel during corporate business development initiatives such as conducting due diligence on the acquisitions of, and investments in, unique products and services businesses. He also advises clients when assessing and acquiring new product or service platforms in support of global business growth strategies.
Mr. Posorske’s practice focuses on the representation of technology-based companies of all sizes in matters relating to patents and technology licenses and strategic counseling on the structure and enforcement of intellectual property portfolios. He has legal and patent experience with everything from novel proteins and recombinant DNA to monoclonal antibodies, biopharmaceuticals, plant patents and more. Additionally, Mr. Posorske has significant research experience as an industrial research scientist in the fields of enzymology, biotechnology, food processing, papermaking, and biomass-to-energy conversion.
For clients, Mr. Posorske has prepared and prosecuted domestic and international patent applications, including re-examination, interference, and appeals. He’s also opposed and defended more than 25 patent oppositions before five different jurisdictions, including the European, Japanese, and Korean Patent Offices. Furthermore, Mr. Posorske has experience drafting and negotiating patent and technology licenses and joint development agreements for medical devices, diagnostic techniques, and nutritional products.
Mr. Stelter received his JD from the University of Dayton School of Law, his BS, with honors, in Mechanical Engineering, from the University of Wisconsin-Platteville and his MSc in Mechanical/Aerospace Engineering from the University of Dayton Graduate School of Engineering. Mr. Posorske earned his JD from Georgetown University Law Center, his Ph.D. from Cornell University, and his BA from the University of Wisconsin.
Arent Fox is one of the few go-to firms for novel and high-profile patent issues. Clients seek us out for our creativity and business approach to their legal issues. With more than 60 full-time patent professionals, we offer a full range of services related to the acquisition, enforcement, and commercial exploitation of patent rights and assets.